Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
Oliver G. Ottmann(Cardiff University), Philippe Rousselot(Université Paris-Saclay), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse), Sébastien Maury(Assistance Publique – Hôpitaux de Paris), Karsten Spiekermann(German Cancer Research Center), Chantal Himberlin(Centre Hospitalier Universitaire de Reims), Pascal Turlure(Centre Hospitalier Universitaire de Limoges), Nicola Goekbuget(Goethe University Frankfurt), Patrice Chevallier(Hotel Dieu Hospital), Joachim Beck(Unknown), Albrecht Reichle(University Hospital Regensburg), Knut Wendelin(Klinikum Arnsberg), Stéphane Leprêtre(Normandie Université), Jean‐Yves Cahn, Emmanuel Raffoux(Inserm), Wolfram Jung(University of Göttingen), Andreas Viardot(University Hospital Ulm), Martine Escoffre‐Barbe(Université Rennes 2), Josep‐María Ribera(Universitat Autònoma de Barcelona), Dieter Hoelzer(Endokrinologikum), Jean‐Michel Cayuela(Inserm), Hervé Dombret(University of London Institute in Paris), Françoise Isnard(Sorbonne Université), Laurence Sanhès(Centre Hospitalier de Perpignan)
Cited by 51
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k